The antiviral drug letermovir (Prevymis), which targets cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4 /CD8 T cell ratios, and better physical function in HIV patients who were receiving effective antiretroviral therapy, a study showed at the 2025 Conference on Retroviruses and Opportunistic Infections in San Francisco. Based on the findings, letermovir “may be the most…